NRx Pharmaceuticals (NRXP) Competitors $3.48 -0.17 (-4.66%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.44 -0.04 (-1.15%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXP vs. MNPR, ELDN, ESPR, VYGR, DERM, DMAC, OGI, CYBN, FDMT, and SLNShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Monopar Therapeutics (MNPR), Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), Voyager Therapeutics (VYGR), Journey Medical (DERM), DiaMedica Therapeutics (DMAC), Organigram (OGI), Cybin (CYBN), 4D Molecular Therapeutics (FDMT), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Its Competitors Monopar Therapeutics Eledon Pharmaceuticals Esperion Therapeutics Voyager Therapeutics Journey Medical DiaMedica Therapeutics Organigram Cybin 4D Molecular Therapeutics Silence Therapeutics NRx Pharmaceuticals (NASDAQ:NRXP) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking. Does the media refer more to NRXP or MNPR? In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Monopar Therapeutics. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 6 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.05 beat NRx Pharmaceuticals' score of 0.54 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NRXP or MNPR more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -449.16% Monopar Therapeutics N/A -107.21%-87.57% Which has stronger earnings & valuation, NRXP or MNPR? Monopar Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$30.15M-$2.01-1.73Monopar TherapeuticsN/AN/A-$8.40M-$3.48-9.96 Which has more risk & volatility, NRXP or MNPR? NRx Pharmaceuticals has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Do analysts prefer NRXP or MNPR? NRx Pharmaceuticals currently has a consensus target price of $28.50, suggesting a potential upside of 718.97%. Monopar Therapeutics has a consensus target price of $55.33, suggesting a potential upside of 59.69%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe NRx Pharmaceuticals is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community believe in NRXP or MNPR? Monopar Therapeutics received 20 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 96.30% of users gave NRx Pharmaceuticals an outperform vote while only 71.88% of users gave Monopar Therapeutics an outperform vote. CompanyUnderperformOutperformNRx PharmaceuticalsOutperform Votes2696.30% Underperform Votes13.70%Monopar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% Do institutionals and insiders believe in NRXP or MNPR? 4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 19.0% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryNRx Pharmaceuticals beats Monopar Therapeutics on 11 of the 16 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.17M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-1.638.7827.1720.06Price / SalesN/A255.64410.88157.10Price / CashN/A65.8538.2534.64Price / Book-2.526.557.094.70Net Income-$30.15M$143.93M$3.23B$247.88M7 Day Performance18.37%3.97%2.91%2.66%1 Month Performance67.31%11.32%9.09%6.40%1 Year Performance2.96%4.20%31.75%14.07% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals2.1222 of 5 stars$3.48-4.7%$28.50+719.0%+4.8%$60.17MN/A-1.632MNPRMonopar Therapeutics3.3155 of 5 stars$30.01-5.4%$55.33+84.4%+750.4%$183.51MN/A-15.2310News CoveragePositive NewsELDNEledon Pharmaceuticals2.6444 of 5 stars$3.06+2.0%$12.50+308.5%+3.4%$183.24MN/A-1.5210Positive NewsESPREsperion Therapeutics4.0852 of 5 stars$0.92+8.1%$6.25+580.4%-58.3%$182.07M$259.57M-1.44200Options VolumeAnalyst RevisionVYGRVoyager Therapeutics4.4313 of 5 stars$3.29+20.1%$13.39+307.0%-61.0%$182.06M$66.96M4.63100Trending NewsAnalyst RevisionGap UpHigh Trading VolumeDERMJourney Medical2.3561 of 5 stars$7.81-3.1%$9.88+26.4%+21.7%$181.94M$56.24M-8.3190Positive NewsShort Interest ↑High Trading VolumeDMACDiaMedica Therapeutics1.3602 of 5 stars$4.17+1.5%$8.00+91.8%+54.4%$178.82MN/A-7.4520Short Interest ↑OGIOrganigram0.6508 of 5 stars$1.31-3.0%N/A-7.3%$175.39M$194.09M-3.45860Positive NewsGap UpCYBNCybin2.118 of 5 stars$8.10+1.8%$86.00+961.7%N/A$173.96MN/A-1.8550Analyst RevisionFDMT4D Molecular Therapeutics2.8555 of 5 stars$3.75+3.6%$29.56+688.1%-81.3%$173.72M$23K-1.32120Analyst RevisionSLNSilence Therapeutics2.9132 of 5 stars$5.73-1.9%$33.83+490.5%-74.9%$171.50M$27.70M-3.65100Positive News Related Companies and Tools Related Companies Monopar Therapeutics Alternatives Eledon Pharmaceuticals Alternatives Esperion Therapeutics Alternatives Voyager Therapeutics Alternatives Journey Medical Alternatives DiaMedica Therapeutics Alternatives Organigram Alternatives Cybin Alternatives 4D Molecular Therapeutics Alternatives Silence Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXP) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRXP Stock Free NRXP Stock Alerts